Retatrutide 15mg

Retatrutide 15mg peptide is an experimental weight loss medication currently undergoing Phase 3 clinical trials. Developed by Eli Lilly, it is a triple-receptor agonist that targets GLP-1, GIP, and glucagon receptors, aiming to enhance fat burning, reduce appetite, and improve insulin sensitivity. In Phase 2 trials, participants receiving 15mg doses lost up to 22.5% of their body weight over 72 weeks, outperforming existing treatments like semaglutide and tirzepatide. Retatrutide 15mg peptide